Drug Profile

Anti-EGFRvIII chimeric antigen receptor T cell therapy - Suzhou Maximum Biotech

Alternative Names: Anti-EGFRvIII CAR T cell therapy - Suzhou Maximum Biotech; EGFRvIII CAR-T cell therapy - Suzhou Maximum Bio-tech

Latest Information Update: 28 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Dec 2022 No recent reports of development identified for preclinical development in Glioma(Late-stage disease) in China (IV, Infusion)
15 Feb 2019 Suzhou Maximum Biotech plans a phase I trial for Glioma (Late-stage disease) in China (ChiCTR1900020829 )

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com